# Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

> **NCT04172805** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 70 (estimated)

## Conditions studied

- Sarcoma,Soft Tissue

## Interventions

- **DRUG:** anlotinib and toripalimab

## Key facts

- **NCT ID:** NCT04172805
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-13
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-05-15
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04172805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04172805, "Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04172805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*